Advertisement

Topics

Manufacturing agreement announced for development of Tildrakizumab

08:15 EDT 5 Jul 2017 | EPM Magazine

Sun Pharma and Samsung BioLogics have entered into a long-term manufacturing agreement for an investigational IL-23p19 inhibitor, Tildrakizumab, for the treatment of moderate to severe plaque psoriasis.

Original Article: Manufacturing agreement announced for development of Tildrakizumab

NEXT ARTICLE

More From BioPortfolio on "Manufacturing agreement announced for development of Tildrakizumab"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...